Navigation Links
Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
Date:4/10/2008

EXTON, Pa., April 10 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it will release its earnings results for its third quarter ended March 31, 2008 at 7:00 A.M. Eastern Time on Tuesday, April 29, 2008.

Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Tuesday, April 29, 2008 at 9:00 A.M. Eastern Time.

To participate in the teleconference call, dial 1-612-234-9959. The teleconference call will also be available for replay starting Tuesday, April 29, 2008 at 11:00 A.M. Eastern Time through Tuesday, May 6, 2008 at 11:59 A.M. Eastern Time by dialing 1-800-475-6701 with an access code of 918341.

Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com. To listen to the live teleconference call, please go to the http://www.kenseynash.com website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com website and may be accessed following the teleconference.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also commercialized a series of innovative products through its own direct endovascular sales force. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
2. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
3. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
6. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. BioElectronics Corporation Announces Singapore and Malaysia Sales
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... -- The immunohistochemistry (IHC) market is projected to ... 7.3% during the forecast period of 2016 to 2021 dominated by ... for the largest share of immunohistochemistry (IHC) market, by end user. ... , , ... spread across 225 pages, profiling 10 companies and supported with 181 ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
Breaking Biology Technology:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):